ScreenerHero

PHR Pharmena S.A.

GPW · PL · Healthcare · Biotechnology · pharmena.eu
3.060PLN0.00%Mkt Cap: 8.63M $P/E: —

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap8.63M USD
Enterprise Value8.60M USD
Revenue (TTM)370.01K USD
Gross Profit332.53K USD
Net Income (TTM)-701.28K USD
Revenue/Share0.13 PLN
Last Price3.060 PLN
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLPHRMN00011
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-10.28
EV/Revenue23.25
P/S23.33
P/B4.17
EPS (TTM)-0.27
EPS (Forward)—
52W Range
2.50031% of range4.320
52W High4.320 PLN
52W Low2.500 PLN
Profitability
Gross Margin83.26%
Oper. Margin-433.88%
EBITDA Margin-226.15%
Profit Margin-175.59%
ROE-28.70%
ROA-25.35%
Growth
Revenue Growth-37.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-833.23K USD
CapEx (TTM)1.92M USD
FCF Margin85.29%
FCF Yield3.66%
Net Debt-27.10K USD
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity0.04
Current Ratio6.69
Quick Ratio0.99
Book Value/Sh0.73 PLN
Cash/Share0.04 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 PLN
Div. Yield0.00%
5Y Avg Yield0.58%
Payout Ratio0.00%
Ex-Div DateApr 9, 2024
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.14M
Float3.31M
Insiders70.30%
Institutions1.86%
Technical
SMA 503.132 (-2.3%)
SMA 2003.274 (-6.5%)
Beta0.50
S&P 52W Chg14.58%
Avg Vol (30d)1.69K
Avg Vol (10d)861
Technical Indicators
RSI (14)42.7
MACD-0.0348
MACD Signal-0.0279
MACD Hist.-0.0069
BB Upper3.296 PLN
BB Middle3.137 PLN
BB Lower2.978 PLN
BB Width10.12%
ATR (14)0.1160 PLN
Vol Ratio (20d)1.90x